PML AS A POTENTIAL PREDICTIVE FACTOR OF EFFICACY OF OXALIPLATIN BASED FIRST LINE CHEMOTHERAPY IN COLORECTAL CANCER PATIENTS

被引：0
|
作者：
Vincenzi, B. [1 ]
Perrone, G. [1 ]
Santini, D. [1 ]
Loupakis, F. [2 ]
Graziano, F. [3 ]
Ruzzo, A. [4 ]
Venditti, O. [1 ]
OnettiMuda, A. [1 ]
Falcone, A. [2 ]
Tonini, G. [1 ]
机构：
[1] Univ Campus Biomed Rome, Rome, Italy
[2] Ist Toscano Tumori, Dept Oncol, Livomo, Italy
[3] Hosp Pesaro, Med Oncol Unit, Pesaro, Italy
[4] Univ Urbino, Dept Biomol Sci, I-61029 Urbino, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：67 / 67
页数：1
相关论文
共 50 条
  • [1] PML AS A POTENTIAL PREDICTIVE FACTOR OF EFFICACY OF OXALIPLATIN BASED FIRST LINE CHEMOTHERAPY IN COLORECTAL CANCER PATIENTS
    Vincenzi, Bruno
    Perrone, Giuseppe
    Santini, Daniele
    Loupakis, Fotios
    Graziano, Francesco
    Ruzzo, Annamaria
    Venditti, Olga
    Muda, Andrea Onetti
    Falcone, Alfredo
    Tonini, Giuseppe
    ANNALS OF ONCOLOGY, 2009, 20
  • [2] PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients
    Vincenzi, Bruno
    Santini, Daniele
    Perrone, Giuseppe
    Graziano, Francesco
    Loupakis, Fotios
    Schiavon, Gaia
    Frezza, Anna Maria
    Ruzzo, Anna Maria
    Rizzo, Sergio
    Crucitti, Pierfilippo
    Galluzzo, Sara
    Zoccoli, Alice
    Rabitti, Carla
    Muda, Andrea Onetti
    Russo, Antonio
    Falcone, Alfredo
    Tonini, Giuseppe
    JOURNAL OF CELLULAR PHYSIOLOGY, 2012, 227 (03) : 927 - 933
  • [3] Efficacy and Safety of Oxaliplatin-based Regimens as First-line Chemotherapy in Elderly Patients With Metastatic Colorectal Cancer
    Yamamoto, Seiji
    Fujii, Hironori
    Murayama, Kotaro
    Iihara, Hirotoshi
    Watanabe, Daichi
    Yamada, Yunami
    Kobayashi, Ryo
    Kiyama, Shigeru
    Makiyama, Akitaka
    Urano, Kimihiko
    Matsuhashi, Nobuhisa
    Matsuura, Katsuhiko
    Suzuki, Akio
    ANTICANCER RESEARCH, 2023, 43 (11) : 5099 - 5105
  • [4] Identification of an immunological prognostic factor for metastatic colorectal cancer patients treated with first-line oxaliplatin-based chemotherapy
    Tada, K.
    Shoji, H.
    Kitano, S.
    Nishimura, T.
    Shimada, Y.
    Nagashima, K.
    Ito, A.
    Honma, Y.
    Iwasa, S.
    Okita, N.
    Takashima, A.
    Kato, K.
    Yamada, Y.
    Katayama, N.
    Boku, N.
    Heike, Y.
    Hamaguchi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S80 - S80
  • [5] Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy
    Bahrami, Afsane
    Amerizadeh, Forouzan
    Hassanian, Seyed Mahdi
    ShahidSales, Soodabeh
    Khazaei, Majid
    Maftouh, Mina
    Ghayour-Mobarhan, Majid
    Ferns, Gordon A.
    Avan, Amir
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (03) : 2193 - 2201
  • [6] Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
    Bécouarn, Y
    Ychou, M
    Ducreux, M
    Borel, C
    Bertheault-Cvitkovic, F
    Seitz, JF
    Nasca, S
    Nguyen, TD
    Paillot, B
    Raoul, JL
    Duffour, J
    Fandi, A
    Dupont-André, G
    Rougier, P
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2739 - 2744
  • [7] Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients
    Park, Hanla A.
    Edelmann, Dominic
    Canzian, Federico
    Seibold, Petra
    Harrison, Tabitha A.
    Hua, Xinwei
    Shi, Qian
    Silverman, Allison
    Benner, Axel
    Macauda, Angelica
    Schneider, Martin
    Goldberg, Richard M.
    Alberts, Steven R.
    Hoffmeister, Michael
    Brenner, Hermann
    Chan, Andrew T.
    Peters, Ulrike
    Newcomb, Polly A.
    Chang-Claude, Jenny
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (09) : 1623 - 1634
  • [8] CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy
    Narita, Yukiya
    Taniguchi, Hiroya
    Komori, Azusa
    Nitta, Sohei
    Yamaguchi, Kazuhisa
    Kondo, Chihiro
    Nomura, Motoo
    Kadowaki, Shigenori
    Takahari, Daisuke
    Ura, Takashi
    Andoh, Masashi
    Muro, Kei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (02) : 409 - 416
  • [9] CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy
    Yukiya Narita
    Hiroya Taniguchi
    Azusa Komori
    Sohei Nitta
    Kazuhisa Yamaguchi
    Chihiro Kondo
    Motoo Nomura
    Shigenori Kadowaki
    Daisuke Takahari
    Takashi Ura
    Masashi Andoh
    Kei Muro
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 409 - 416
  • [10] Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer
    Sorbye, Halfdan
    Berglund, Ake
    Tveit, Kjell Magne
    Ogreid, Dagfinn
    Wanderas, Eva Hoff
    Wentzel-Larsen, Tore
    Dahl, Olav
    Glimelius, Bengt
    ACTA ONCOLOGICA, 2007, 46 (07) : 982 - 988
12345